Form 4: Revolution Medicines' General Counsel, Jeff Cislini, Executes Stock Option and Sells Shares Under 10b5-1 Plan

Jeff Cislini, General Counsel of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On November 6, 2024, Jeff Cislini, the General Counsel of Revolution Medicines, exercised stock options to acquire 6,000 shares of common stock at a price of $36.57.
• Simultaneously, Cislini sold 6,000 shares of Revolution Medicines' common stock at $60 per share.
• These transactions were executed under a pre-arranged 10b5-1 trading plan adopted on March 20, 2024.
• Following these transactions, Cislini beneficially owns 45,634 shares of common stock, which includes 40,209 restricted stock units, and holds options for 30,000 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document simply reports stock transactions by an executive under a pre-arranged plan. It doesn't inherently indicate positive or negative news about the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Industry Context

Executive stock transactions are common and closely monitored, especially in the biopharmaceutical industry. The use of 10b5-1 plans is a standard practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• Executive compensation packages in the biopharmaceutical industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the pharmaceutical sector like Amgen, Gilead Sciences, and Vertex Pharmaceuticals, to manage their personal finances while avoiding potential insider trading accusations.
• The size and frequency of stock transactions by executives vary widely depending on their compensation structure, company performance, and individual financial planning needs.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares involved.

Key Dates